loader2
Login Open ICICI 3-in-1 Account

IOL Chemicals & Pharmaceuticals Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
IOL Chemicals and Pharmaceuticals Ltd. 11 Nov 2025 18:22 PM

Q2FY26 Quarterly Result Announced for IOL Chemicals and Pharmaceuticals Ltd.

Pharmaceuticals company IOL Chemicals and Pharmaceuticals announced Q2FY26 results

  • Revenue from Operations: Rs 567.5 crore against Rs 525.8 crore during Q2FY25, change 7.9%.
  • EBITDA: Rs 64.0 crore against Rs 48.0 crore during Q2FY25, change 33.3%.
  • EBITDA Margin: 11.1% for Q2FY26.
  • PAT: Rs 30.0 crore against Rs 19.2 crore during Q2FY25, change 56.7%.
  • PAT Margin: 5.2% for Q2FY26.

Vikas Gupta, Joint Managing Director, said: “Q2FY26 reflects IOL’s continued operational strength and strategic focus, with revenue from operations rising 7.9% and EBITDA improving 33.3% YoY. Importantly, EBITDA margin improved to 11.1% from 9.1%, driven by better operating leverage and cost efficiencies.

Profit After Tax increased 56.7% YoY with PAT margin expanding to 5.2% from 3.6%, underscoring the strength of our integrated model. However, PAT was marginally impacted on a sequential basis due to higher fuel costs, following the Punjab floods, which temporarily disrupted supply chains and elevated energy inputs.

Both our Pharmaceuticals and Chemicals segments reported YoY EBIT growth, reflecting improved operating discipline and recovery in volumes. The Pharmaceuticals segment continues to gain momentum, led by strong traction in non-Ibuprofen APIs.

We also incorporated IOL Pharmaxis UK Limited, a strategic step to strengthen our international operations and improve customer proximity in key regions. In the Chemicals segment, we are witnessing steady volume recovery, even as pricing remains under pressure. Going ahead, our focus remains on cost optimisation, process discipline, and maintaining a balanced product mix across end-use sectors.”

Result PDF

Pharmaceuticals company IOL Chemicals and Pharmaceuticals announced Q1FY26 results

  • Revenue from Operations: Rs 551.7 crore compared to Rs 502.4 crore during Q1FY25, change 9.8%.
  • EBITDA: Rs 69.5 crore compared to Rs 58.2 crore during Q1FY25, change 19.5%.
  • EBITDA Margin: 12.4% for Q1FY26.
  • PAT: Rs 34.0 crore compared to Rs 29.7 crore during Q1FY25, change 14.4%.
  • PAT Margin: 6.1% for Q1FY26.

Vikas Gupta, Joint Managing Director, said: “We are delighted to report an outstanding start to FY26, with Q1 results reflecting strong execution and strategic clarity. Despite challenging macroeconomic Conditions and pricing pressures, with several key product prices having bottomed out, IOL has delivered impressive performance, underscoring the resilience of our integrated business model.

Our continued focus on portfolio diversification is yielding results, with non-Ibuprofen APIs gaining traction across global markets. With the commissioning of our fully backwardintegrated Paracetamol production unit, we are increasing our presence in both regulated and non-regulated markets. This positions us well to capture emerging opportunities, especially in regions where quality and compliance remain key differentiators.

In the chemicals segment, the successful REACH registration of Acetic Anhydride under EU norms opens up new growth avenues in Europe, reinforcing our commitment to global standards and market expansion. As we move forward, our priorities remain clear — to scale high-value APIs, deepen our export footprint, and drive operational excellence. With a robust balance sheet and a strong innovation pipeline, we are confident in our ability to deliver sustainable growth and long-term value for all stakeholders.”

Result PDF

Pharmaceuticals company IOL Chemicals and Pharmaceuticals announced Q4FY25 & FY25 results

Q4FY25 Financial Highlights:

  • Revenue from Operations: Rs 527.8 crore (4.7% YoY growth)
  • Gross Profit: Rs 186.5 crore (-1.3% YoY decline)
  • Gross Margin: 35.0% (-190 bps YoY)
  • EBITDA: Rs 67.5 crore (17.1% YoY growth)
  • EBITDA Margin: 12.7% ( 141 bps YoY)
  • Profit After Tax (PAT): Rs 31.6 crore (12.2% YoY growth)
  • PAT Margin: 5.9% ( 43 bps YoY)
  • Cash Profit After Tax: Rs 56.4 crore (14.6% YoY growth)

FY25 Financial Highlights:

  • Revenue from Operations: Rs 2,079.2 crore (compared to Rs 2,132.8 crore in FY24)
  • Gross Profit: Rs 709.8 crore (compared to Rs 765.9 crore in FY24)
  • Gross Margin: 33.8% (compared to 35.4% in FY24)
  • EBITDA: Rs 224.6 crore (compared to Rs 261.6 crore in FY24)
  • EBITDA Margin: 10.7% (compared to 12.1% in FY24)
  • Profit After Tax (PAT): Rs 101.0 crore (compared to Rs 135.4 crore in FY24)
  • PAT Margin: 4.8% (compared to 6.3% in FY24)
  • Cash Profit After Tax: Rs 185.1 crore (compared to Rs 208.5 crore in FY24)

Commenting on the performance, Vikas Gupta, Joint Managing Director said, “In Q4FY25, we delivered sustainable performance, with the Ibuprofen segment showing improved traction despite intense competition and continued pricing pressure in global markets. A key highlight was the successful commissioning of our fully backward-integrated Paracetamol production unit, with an installed capacity of 10,800 MTPA. This has tripled our Paracetamol capacity, enabling us to strengthen our non-Ibuprofen portfolio, particularly in high-demand, fast-moving therapeutic categories. Notably, pricing and demand across our broader API basket remained stable. However the chemicals segment delivered stable performance despite muted volumes, as enhanced operational efficiencies across key units contributed to a notable improvement in EBIT.

FY25 was marked by strategic consolidation and investments focused on capacity enhancement, improved utilization, cost control, and regulatory expansion. Our strong backward integration model continues to drive cost control, supply reliability, and operating leverage. We remain committed to strengthening our portfolio, driving operational excellence, and expanding our market reach to create sustained value.”

Result PDF

Pharmaceuticals company IOL Chemicals and Pharmaceuticals announced Q3FY25 results

  • Total Income: Rs 527.37 crore compared to Rs 528.77 crore during Q3FY24, change -0.26%.
  • EBITDA: Rs 50.94 crore compared to Rs 52.86 crore during Q3FY24, change -3.63%.
  • EBITDA margin: 9.66% for Q3FY25.
  • PAT: Rs 20.55 crore compared to Rs 23.23 crore during Q3FY24, change 11.5%.
  • PAT margin: 3.90% for Q3FY25.

Vikas Gupta, Joint Managing Director, said: “We are pleased to report our Q3FY25 Results as despite challenges such as pricing pressures, stagnant demand, and intense market competition, the company has successfully maintained stable and sustainable performance. This resilience reflects our strategic approach and adaptability in a dynamic business environment.

Confident of our resilient performance, the Board has declared an interim dividend of Rs 4/- (40%) per share of face value of Rs 10 each for FY25 and fixed a Record Date for 18th February 2025 for ascertaining the entitlement. Moving forward, we remain committed to our longterm vision by focusing on market diversification and expansion to unlock new growth opportunities. Additionally, we are implementing comprehensive cost optimization measures to enhance operational efficiency, improve profitability, and reinforce our competitive position. ”

Result PDF

Pharmaceuticals company IOL Chemicals and Pharmaceuticals announced H1FY25 & Q2FY25 results

Q2FY25 Financial Highlights:

  • Total Income: Rs 532.18 crore compared to Rs 552.41 crore during Q2FY24, change -3.66% YoY.
  • EBITDA: Rs 47.99 crore compared to Rs 71.21 during Q2FY24, change -32.61% YoY.
  • EBITDA Margin: 9.02% for Q2FY25.
  • PAT: Rs 19.15 crore compared to Rs 37.79 crore during Q2FY24, change -49.33 YoY.
  • PAT Margin: 3.60% for Q2FY25.

H1FY25 Financial Highlights:

  • Total Income: Rs 1041.94 crore compared to Rs 1122.65 crore during H1FY24, change -7.19% YoY.
  • EBITDA: Rs 106.17 crore compared to Rs 151.13 during H1FY24, change -29.75% YoY.
  • EBITDA Margin: 10.19% for H1FY25.
  • PAT: Rs 48.83 crore compared to Rs 84.00 crore during H1FY24, change -41.87%YoY.
  • PAT Margin: 4.69% for H1FY25.

Vikas Gupta, Joint Managing Director, said: "We are pleased to report sustainable revenue growth in Q2FY25, reflecting the resilience of our core business. However, we faced some margin pressure during the quarter, driven by challenges in selling price. To address this, we are taking proactive measures to optimize marketing strategies, cost structure and enhance operational efficiencies, with the goal of improving profitability in the coming periods. Despite these challenges, we remain confident in the long-term growth potential of the business."

Result PDF

Pharmaceuticals company IOL Chemicals and Pharmaceuticals announced Q1FY25 results:

  • Total Income: Rs 509.8 crore (decreased by 0.3% QoQ, decreased by 10.6% YoY) 
  • EBITDA: Rs 58.2 crore (increased by 1.0% QoQ, decreased by 27.2% YoY)
  • EBITDA Margin: 11.4% (increased by 10 basis points QoQ, decreased by 260 basis points YoY)
  • PAT: Rs 29.7 crore (increased by 5.3% QoQ, decreased by 35.7% YoY)
  • PAT Margin: 5.8% (increased by 30 basis points QoQ, decreased by 230 basis points YoY)

Commenting on the performance, Vikas Gupta, Joint Managing Director said, “Despite facing challenging geopolitical conditions, the Company has successfully maintained operational performance, demonstrating resilience in absorbing the pricing volatility of raw materials for chemicals and intermediates. With the recent approvals from various regulatory authorities, we are excited to explore untapped opportunities in regulated markets. Our commitment to enhancing operational efficiency remains steadfast as we embrace cutting-edge technology, all while striving to minimize our carbon footprint. We are dedicated to driving sustainable growth and setting new benchmarks in our industry.”

Result PDF

IOL Chemicals and Pharmaceuticals announced Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

  • Total income at Rs 511 crore against Rs 596 crore 
  • EBITDA at Rs 57.6 crore against Rs 104.5 crore
  • Net profit at Rs 28.2 crore against Rs 65.3 crore 

FY24 Financial Highlights:

  • Total income at Rs 2,162.9 crore against Rs 2,242.7 crore
  • EBITDA up 3.8% YoY to Rs 261.6 crore
  • Net profit at Rs 135 crore against Rs 140 crore 

Commenting on the performance, Vikas Gupta, Joint Managing Director said, “The Company has exhibited resilient financial performance in FY24 despite challenging macro-economic environment and volatile chemical sector trajectory. We are receiving positive response in export market despite geopolitical uncertainties and supply chain obstacles. Though, the revenue growth has been sluggish, the margins were stable following Company’s sustained cost control initiatives. We believe that chemical sector turbulence would likely stabilize this financial year. In the nonIbuprofen segment, we are on track to expand our footprints in key regulated markets following approvals and certifications received last year. During the year the capex in infrastructure and automization will improve the operational efficiency and reduce the carbon footprint.”

Result PDF

IOL Chemicals and Pharmaceuticals announced Q1FY24 results:

  • Total income for Q1FY24 stood at Rs 570 crore at the same level of Rs 570 crore in Q1FY23
  • EBITDA for Q1FY24 at Rs 80 crore as compared to Rs 61 crore in Q1FY23
  • Net profit for Q1FY24 at Rs 46 crore as compared to Rs 35 crore in Q1FY23

Commenting on the performance, Vikas Gupta, Joint Managing Director, said, “We are pleased to report sustainable performance during Q1FY24, tackling present challenges while positioning ourselves for forthcoming opportunities. We are hopeful for an increased presence in regulatory markets as the Company got CEP for paracetamol. Additionally, with the commencement of the Acetic Anhydride plant, focus on improved efficiencies, product mix, and timely execution we are hopeful to generate strong cash flow”.

 

Result PDF

IOL Chemicals and Pharmaceuticals announced Q4FY23 & FY23 result:

  • Q4FY23:
    • Total income for Q4FY23 stood at Rs 596 crore as against Rs 530 crore in Q3FY23
    • EBITDA for Q4FY23 at Rs 104 crore as compared to Rs 50 crore in Q3FY23
    • Net profit for Q4FY23 at Rs 65 crore as compared to Rs 24 crore in Q3FY23
  • FY23:
    • Total income for FY23 stood at Rs 2,243 crore as compared to Rs 2,216 crore in FY22
    • EBITDA for FY23 at Rs 252 crore as compared to Rs 288 crore in FY22
    • Net profit for FY23 at Rs 140 crore as compared to Rs 166 crore in FY22

Commenting on the performance, Vikas Gupta, Joint Managing Director said, “The last quarter of the financial year has come out strong for us as we stabilized our operations in pharma and specialty chemicals segments with a focus on cost rationalisation and margin improvement.

With significant operational, technical and commercial efficiencies, improved market combination and expecting sustainable demand as an alternative to China, we believe we are on a good upward trajectory."

 

 

 

Result PDF

 IOL Chemicals and Pharmaceuticals announced Q3FY23 results:

  • Q3FY23:
    • Total income stood at Rs 530 crore against Rs 546 crore QoQ and Rs 564 crore YoY
    • EBITDA at Rs 50 crore as compared to Rs 37 crore QoQ and Rs 68 crore YoY
    • Net profit of the company at Rs 24.15 crore against Rs 15.67 crore QoQ and Rs 40.07 crore YoY
    • Paracetamol capacity expansion by 1,800 MTPA completed
    • Company focusing on frugal manufacturing practices to reduce raw material costs and expand margins

Commenting on the quarterly performance, Dr Sanjay Chaturvedi, Executive Director & CEO said, “The quarterly performance reflects our commitment to control our costs and improve our margin trajectory. For the third quarter, EBITDA and net profit margins – both improved sequentially. Apart from cost rationalisation, we have completed our capacity enhancement of Paracetamol by 1,800 MTPA to take total capacity to 3,600 MTPA with backward integration of Para Amino Phenol (PAP) and we expect this capacity enhancement to boost volume growth from next quarter onwards.”

 

Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app